Status:
UNKNOWN
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended
Lead Sponsor:
University Hospital Tuebingen
Collaborating Sponsors:
Heart and Diabetes Center North Rhine-Westphalia
Conditions:
Anticoagulation With Direct Oral Anticoagulants
Eligibility:
All Genders
18+ years
Brief Summary
The investigators' study aims to test the correlation between CoaguChek point-of-care aPTT testing (Roche, Switzerland) and low plasma levels of all four currently EMA approved direct oral anticoagula...
Detailed Description
In emergency situations such as an acute stroke or emergency surgery, information on the plasma concentration of DOAC in patients with suspected or known intake of DOAC plays a vital role in making de...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Stroke patients, who were newly started on oral anticoagulation with apixaban, edoxaban, dabigatran or rivaroxaban for secondary prevention of thromboembolic events
- informed consent
Exclusion
- Vitamin K antagonists ≤ 14 days prior to study participation
- Prior DOAC intake ≤ 72 hours
- Low-molecular weight heparin ≤ 24 hours
- Unfractionated heparin ≤ 12 hours
- Heparinoids (e.g. Fondaparinux) ≤ 72 hours
- Abnormal coagulation values at baseline (Quick \< 70% or activated thromboplastin time (aPTT) \> 40sec.)
- History of coagulopathy
Key Trial Info
Start Date :
January 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04679298
Start Date
January 5 2021
End Date
August 31 2023
Last Update
June 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Tuebingen
Tübingen, Germany, 72070